SAM #75N98026Q00467

Licensing Fee Renewal for B-hIL2RA Transgenic Mouse Strain for Cancer Research

The National Institutes of Health (NIH), through the Office of Logistics and Acquisition Operations (OLAO) and the National Cancer Institute's Center for Cancer Research, Molecular Imaging Branch (MIB), is seeking to renew the licensing fee for the B-hIL2RA transgenic mouse strain. - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Cancer Institute (NCI), Center for Cancer Research, Molecular Imaging Branch (MIB) - OEMs and Vendors: - No specific OEMs or vendors are named in the available documentation - Products/Services Requested: - Renewal of licensing fee for B-hIL2RA transgenic mouse strain - B-hIL2RA mice express the human form of IL2RA (CD25) - Used in pre-clinical research on photoimmunotherapy (PIT) targeting regulatory T cells (Tregs) to enhance anti-cancer immune responses - Supports development of targeted imaging agents and therapies (MRI, PET, radionuclide, optical probes) - Unique/Notable Requirements: - The B-hIL2RA mouse model is specialized and critical for evaluating treatment materials intended for human application - The procurement is solely for the renewal of the licensing fee for this specific transgenic mouse strain - No physical product delivery; the focus is on continued legal access to use the mouse model in research

Description

The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed on regulatory T cells (Tregs). These cells can reduce the immune system’s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses. 

To support this research, MIB uses a transgenic mouse strain known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future human application. As a result, this mouse strain has proven invaluable in the MIB’s ongoing research program. 

The MIB is requesting to renew a licensing fee for transgenic mice, B-hIL2RA. B-hIL2RA transgenic mice.

View original listing